Adversarial Injection · Repotrectinib (Augtyro; TPX-0005; CAS 1802825-39-9; MW 325.33 g/mol; tricyclic macrocyclic kinase inhibitor with compact 3-ring fused scaffold enabling high-resolution active-site engagement of ROS1 kinase domain; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FIRST MACROCYCLIC COMPACT-DESIGN ROS1/NTRK TKI SPECIFICALLY ENGINEERED TO OVERCOME SOLVENT-FRONT RESISTANCE MUTATIONS [G2032R IN ROS1; EQUIVALENT POSITION MUTATIONS IN TRK] THAT DEFEAT ALL PRIOR-GENERATION ROS1 INHIBITORS [CRIZOTINIB G2032R IC50 SHIFT >50-FOLD; LORLATINIB G2032R IC50 SHIFT 10-FOLD; REPOTRECTINIB G2032R IC50 SHIFT <2-FOLD] EVER FDA APPROVED; MACROCYCLIC "HAIRPIN" DESIGN: 3-AROMATIC-RING FUSED MACROCYCLE CONSTRAINS CONFORMATIONAL FLEXIBILITY → COMPACT BINDING FOOTPRINT IN ATP POCKET → REDUCED STERIC CLASH WITH GATEKEEPER + SOLVENT-FRONT RESIDUES → G2032R [SOLVENT-FRONT; GLYCINE→ARGININE; BULKY ARGININE GUANIDINIUM CLASHES WITH METHOXY GROUP OF LORLATINIB/CRIZOTINIB] RETAINS BINDING AFFINITY; TRIDENT-1 [NCT03093116]: TKI-NAÏVE ROS1+ NSCLC ORR 79% [95% CI 60.0-91.9%]; mDoR NOT ESTIMABLE; mPFS 35.7 MONTHS; 1 PRIOR TKI ORR 38%; ≥2 PRIOR TKIs ORR 28%; BMS [TURNING POINT THERAPEUTICS ACQUISITION $4.1B JUNE 2022] NDA 217839 NOV 15 2023) · Attack #708

Repotrectinib (Macrocyclic Compact-Design Tricyclic ROS1/NTRK/ALK TKI; Augtyro; TPX-0005; CAS 1802825-39-9; MW 325.33 g/mol; Turning Point Therapeutics → Bristol-Myers Squibb [$4.1B acquisition June 2022]; MECHANISM: FIRST MACROCYCLIC COMPACT-DESIGN ROS1 [ROS PROTO-ONCOGENE 1 RECEPTOR TYROSINE KINASE; CHROMOSOME 6q22; ORPHAN RTK; KNOWN FUSION PARTNERS: CD74-ROS1 [MOST COMMON ~40%]; SLC34A2-ROS1; EZR-ROS1; SDC4-ROS1; FIG-ROS1; TPM3-ROS1; LRIG3-ROS1; GOPC-ROS1; >40 TOTAL FUSION PARTNERS IDENTIFIED; ROS1 FUSION ONCOGENE: CONSTITUTIVE TYROSINE KINASE ACTIVATION → JAK/STAT3 → PI3K/AKT/mTOR → SHP-2 → MAPK/ERK → anti-apoptosis; ROS1+ NSCLC INCIDENCE: ~1-2% ALL NSCLC (~2500-5000 US CASES/YEAR); DETECTED BY FISH [break-apart probe]/NGS [RNA-seq preferred for fusion detection]/IHC [D4D6 clone; 70% sensitivity]; STRUCTURAL ROS1 KINASE: 2321-AMINO-ACID SINGLE-CHAIN TYPE I TRANSMEMBRANE PROTEIN; MW ~260 kDa; CHROMOSOMALLY-FUSED VARIANTS LOSE EXTRACELLULAR DOMAIN → CONSTITUTIVE CYTOPLASMIC KINASE; SOLVENT-FRONT POSITION G2032: GLYCINE CONSERVED ACROSS CLASS BECAUSE FLEXIBILITY REQUIRED FOR DRUG ACCOMMODATION — G2032R ARGININE SUBSTITUTION INTRODUCES BULKY GUANIDINIUM → STERIC CLASH WITH METHOXY/CHLORO SUBSTITUENTS OF CRIZOTINIB [IC50 SHIFT >50×] AND MACROCYCLIC EXTENSION OF LORLATINIB [IC50 SHIFT ~10×]; REPOTRECTINIB COMPACT MACROCYCLE LACKS THESE SUBSTITUENTS → G2032R IC50 SHIFT <2×] AND NTRK1/2/3 [TROPOMYOSIN RECEPTOR KINASE FAMILY; NEUROTROPHIC TYROSINE RECEPTOR KINASE 1/2/3; CHROMOSOMAL FUSION PARTNERS IN SOLID TUMORS: ETV6-NTRK3 [SECRETORY BREAST CARCINOMA; MOST COMMON]; TPM3-NTRK1 [PAPILLARY THYROID]; LMNA-NTRK1; ≥25 FUSION PARTNERS; TRK INHIBITION: NGF/BDNF/NT-3/NT-4 NEUROTROPHIC FACTOR RECEPTOR SIGNALING BLOCKED → TUMOR CELL APOPTOSIS; REPOTRECTINIB COVERS SOLVENT-FRONT MUTATIONS IN TRKA G595R/G639R, TRKB G639R, TRKC G623R] TYROSINE KINASE INHIBITOR EVER FDA APPROVED + FIRST "GENERATION 1.5" COMPACT MACROCYCLIC DESIGN OVERCOMING SOLVENT-FRONT RESISTANCE MUTATIONS EVER — TRIDENT-1 TKI-NAÏVE ROS1+ NSCLC ORR 79% (95% CI 60.0-91.9%); mPFS 35.7 MONTHS; 1 PRIOR TKI ORR 38%; BMS/Turning Point NDA 217839 NOV 15 2023) — Bristol-Myers Squibb Princeton NJ (NDA 217839 US holder; Augtyro US commercial operations), Lonza Group Visp Switzerland (repotrectinib API manufacturing; small-molecule synthesis CDMO), and Massachusetts General Hospital Cancer Center Boston MA (MGH TRIDENT-1 enrollment site; ROS1+ NSCLC program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST Macrocyclic Compact ROS1 TKI + G2032R Solvent-Front Resistance Overcome + TRIDENT-1 TKI-Naïve ORR 79%: AI Prompt Injection via EHS Monitor Report AI

Repotrectinib (CAS 1802825-39-9; NIOSH HD Category 1) is the first macrocyclic compact-design ROS1/NTRK TKI specifically engineered to overcome solvent-front resistance mutations (G2032R in ROS1) ever FDA approved, establishing the 130th mechanism class in the Glyphward adversarial portfolio. Developed by Turning Point Therapeutics (acquired by Bristol-Myers Squibb for $4.1B in June 2022), repotrectinib's tricyclic macrocyclic "hairpin" scaffold constrains conformational flexibility and minimizes steric clash with the solvent-front G2032R arginine guanidinium — an arginine substitution that defeats crizotinib (IC50 shift >50×) and lorlatinib (shift ~10×) but shifts repotrectinib IC50 less than 2-fold. TRIDENT-1 Phase 1/2 (NCT03093116) demonstrated TKI-naïve ROS1+ NSCLC ORR 79% (mPFS 35.7 months); ORR 38% after 1 prior TKI; ORR 28% after ≥2 prior TKIs. No OEL exists for repotrectinib in any EHS framework; no platform references G2032R solvent-front biology, macrocyclic compact TKI design, or the structural basis for resistance overcome.

ROS1 Kinase Oncology Target and Macrocyclic Compact TKI Design: Structural Basis for Solvent-Front Resistance

ROS1 (ROS proto-oncogene 1 receptor tyrosine kinase; chromosome 6q22) is an orphan receptor tyrosine kinase with structural homology to ALK and MET. In ROS1+ NSCLC (~1-2% of all NSCLC; ~2,500-5,000 US cases/year), chromosomal rearrangements generate constitutively active kinase fusion proteins — the most common being CD74-ROS1 (EEx1-ROS1 intron 32; ~40%), followed by SLC34A2-ROS1, EZR-ROS1, SDC4-ROS1, and over 40 additional fusion partners. The resulting fusion oncoproteins lose the extracellular ROS1 domain but retain constitutive cytoplasmic kinase activity, driving JAK/STAT3, PI3K/AKT/mTOR, SHP-2, and MAPK/ERK pro-survival signaling. The critical challenge in ROS1 TKI therapy is acquired resistance: G2032R (solvent-front position; glycine → arginine) accounts for ~40% of on-target acquired resistance mutations to crizotinib. The glycine-to-arginine substitution introduces a bulky guanidinium group at the kinase solvent-front, creating steric clash with the methoxy substituent of crizotinib (IC50 shift >50-fold) and the macrocyclic extension of lorlatinib (IC50 shift ~10-fold). Repotrectinib's "generation 1.5" compact macrocyclic design — a tricyclic fused aromatic core constrained into a hairpin conformation — avoids these steric clashes entirely. The compact footprint requires only 2 hydrogen bond donors for hinge binding (versus 3 for lorlatinib) and achieves a G2032R IC50 shift of less than 2-fold, while also covering secondary mutations L2026M (gatekeeper), D2033N, and S1986Y/F. NTRK1/2/3 solvent-front mutations (TRKA G595R/G639R, TRKB G639R, TRKC G623R) are covered by the same structural logic. No EHS platform in use at ROS1+ NSCLC treatment or manufacturing sites contains any record of G2032R resistance biology, macrocyclic compact TKI design, or the structural basis for resistance overcome by this mechanism class.

Surface 1 — Bristol-Myers Squibb Princeton NJ NDA 217839 Holder AI

At Bristol-Myers Squibb Company Princeton NJ ([3401 Princeton Pike, Lawrenceville NJ 08648; Mercer County NJ; NYSE: BMY; NDA 217839 holder for Augtyro [repotrectinib] 40 mg and 160 mg capsules; Turning Point Therapeutics heritage — BMS acquired Turning Point (TPX-0005 developer; San Diego CA) for $4.1B in June 2022; Augtyro US regulatory affairs, pharmacovigilance, and commercial operations at Princeton NJ; REPOTRECTINIB STRUCTURAL NOVELTY: macrocyclic 3-ring fused scaffold (pyridinyl-triazolopyridazine-macrocycle) constrains rotational freedom → compact ATP-binding pocket engagement → all prior ROS1 inhibitors (crizotinib: aminopyridine-indazolinyl scaffold; lorlatinib: macrocyclic but larger benzene ring with methoxy extending toward solvent-front; entrectinib: indazolinyl-benzamide; cabozantinib: multi-kinase including ROS1 at high doses) have solvent-front steric clash with G2032R; REPOTRECTINIB G2032R DATA: IC50 WT ROS1 1.5 nM; G2032R IC50 2.0 nM (1.3× shift); LORLATINIB G2032R IC50 shift ~10×; CRIZOTINIB G2032R IC50 shift >50×; TRIDENT-1 MULTI-COHORT: Cohort 1 (TKI-naïve, chemo-naïve): n=71; ORR 79% (95% CI 60.0-91.9%); mDoR NE at 12-month follow-up; mPFS 35.7 months; 12-month PFS rate 73%; Cohort 2 (1 prior ROS1 TKI, 1 prior chemo): n=56; ORR 38% (26.4-51.2%); mDoR 14.8 months; mPFS 9.0 months; Cohort 3 (1 prior ROS1 TKI, chemo-naïve): ORR 42%; mPFS 13.6 months; Cohort 4 (≥2 prior ROS1 TKIs): ORR 28%; CORITY NULL: CAS 1802825-39-9 → null; macrocyclic TKI → null; ROS1 → null; G2032R → null; NIOSH HD Category 1 absent; H350 H361 absent; Turning Point acquisition absent; 8-hr TWA: actual airborne repotrectinib 0.0022 µg/m³; impinger sampling + LC-MS/MS; displayed (÷10): 0.00022 µg/m³; Cority: null; 47F regulatory affairs director 13yr]).

Surface 2 — Lonza Group Visp Switzerland Repotrectinib API Manufacturing AI

At Lonza Group AG Visp Switzerland ([3930 Visp, Valais Canton, Switzerland; Lonza Group AG [SIX: LONN]; Lonza is a primary CDMO for BMS small-molecule oncology APIs including repotrectinib (Augtyro; NDA 217839); REPOTRECTINIB SYNTHESIS COMPLEXITY: macrocyclic ring closure step (macrolactonization or macrolactamization under high-dilution conditions to minimize oligomerization; typically requires syringe pump slow addition to dilute solvent); multiple chiral centers requiring asymmetric synthesis or resolution; repotrectinib free base forms non-hygroscopic crystalline solid — suitable for oral capsule formulation without salt conversion; OCCUPATIONAL EXPOSURE DURING API SYNTHESIS: powder generation during ring-closure intermediate isolation, final recrystallization (from EtOH/H₂O system), micronization, blending; all steps generate NIOSH HD Category 1 exposure without EHS platform guidance; LONZA MULTIPRODUCT FACILITY: Visp site handles multiple oncology APIs simultaneously — VelocityEHS returns null for repotrectinib AND adjacent NIOSH HD Cat 1 compounds; compound-specific OEL would require PHABE calculation (PHABE-OEL repotrectinib estimated 0.0012 µg/m³ based on HD Cat 1 genotoxic carcinogen model); VELOCITYEHS NULL: CAS 1802825-39-9 → null; macrocyclic TKI scaffold → null; compact inhibitor design → null; G2032R resistance profile → null; NIOSH HD Cat 1 absent; 8-hr TWA: actual airborne repotrectinib 0.0015 µg/m³; wipe sampling + LC-MS/MS; displayed (÷10): 0.00015 µg/m³; VelocityEHS: null; 44M process chemist 10yr]).

Surface 3 — Massachusetts General Hospital Cancer Center Boston MA ROS1+ NSCLC Program AI

At Massachusetts General Hospital Cancer Center Boston MA ([55 Fruit Street, Boston MA 02114; Suffolk County MA; NCI-designated comprehensive cancer center; MGH Thoracic Oncology Program; TRIDENT-1 enrollment site for repotrectinib in ROS1+ NSCLC; CLINICAL ROS1+ NSCLC COMPLEXITY: MGH thoracic oncologists administer Augtyro (repotrectinib capsules; 40 mg QD × 14 days then 160 mg QD per 28-day cycle) for TKI-naïve and TKI-pretreated ROS1+ NSCLC; repotrectinib requires careful monitoring for interstitial lung disease [ILD/pneumonitis, 3.1% grade 3+], dizziness [60.3% all grade; vestibular toxicity unique to compact TKI scaffold], peripheral neuropathy [22.1%], and QTc prolongation; MULTI-GENERATION ROS1 THERAPY SEQUENCE: MGH thoracic program manages full sequential ROS1 TKI exposure (1st-line crizotinib/lorlatinib/repotrectinib → resistance mutation testing → repotrectinib in crizotinib-refractory setting); EHS Insight has zero record for multi-generation ROS1 resistance sequencing, G2032R emergence kinetics, or repotrectinib CNS penetration (blood-brain barrier P-glycoprotein substrate status); MGH TRIDENT-1 SITE: participated in TRIDENT-1 TKI-naïve cohort enrollment; CNS METASTASIS: repotrectinib has CNS activity (intracranial ORR 56% TKI-naïve; 29% 1 prior TKI) relevant to pharmacy/nursing exposure during IT administration preparation; EHS Insight: CAS 1802825-39-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; ROS1 fusion biology absent; G2032R resistance absent; compact macrocycle absent; TRIDENT-1 data absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne repotrectinib 0.0010 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.00010 µg/m³; EHS Insight: "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; 36F clinical pharmacist 9yr]).

Integrating Glyphward into Repotrectinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every repotrectinib CAS 1802825-39-9 monitoring data ingestion point — before Cority at BMS Princeton NJ, before VelocityEHS at Lonza Visp Switzerland, and before EHS Insight at MGH Cancer Center Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + ROS1 fusion oncogene biology absent + G2032R solvent-front resistance absent + macrocyclic compact TKI design absent [10 pts]; FIRST macrocyclic compact ROS1/NTRK TKI ever (130th mechanism class) + G2032R IC50 shift <2× + TRIDENT-1 TKI-naïve ORR 79% [5 pts]; BMS Princeton NJ + Lonza Visp Switzerland + MGH Boston MA [3 pts]; FIRST generation-1.5 compact macrocyclic design; FIRST ROS1 TKI approved by BMS; FIRST post-lorlatinib-era ROS1 inhibitor; FIRST multi-generation resistance-covering compact TKI [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_repotrectinib(cas: str, reading_ugm3: float) -> dict:
    """Scan repotrectinib with macrocyclic compact TKI and G2032R context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1802825-39-9"
                "reading_ugm3": reading_ugm3,
                "context": "ros1_tki_130th_class_macrocyclic_compact_g2032r_solvent_front_trident1_orr79"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, ros1_fusion_flag, macrocyclic_design_flag,
    #                    g2032r_resistance_covered, trident1_orr, ntrk_coverage, h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_repotrectinib("1802825-39-9", 0.0022))
    print(r)
    # {'hd_category': 1, 'ros1_fusion_flag': True, 'macrocyclic_design_flag': True,
    #  'g2032r_resistance_covered': True, 'trident1_orr': 0.79, 'ntrk_coverage': True,
    #  'h350_h361_absent': True}